Olomouc

• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 10 2024-10-02 Locally advanced or metastatic urothelial cancer
• Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting
  2023-508304-38-00 4 2024-09-10 Ulcerative Colitis (UC)
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting
  2022-501105-12-00 5 2024-07-15 Urothelial Carcinoma
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting
  2023-503699-25-00 5 2024-07-15 Progressive Pulmonary Fibrosis
• A Study of Zanubrutinib Versus Tacrolimus in Participants With Primary Membranous Nephropathy (ALMOND) Recruiting
  2022-501147-32-00 10 2024-07-11 Primary Membranous Nephropathy
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting
  2023-503697-21-01 5 2024-06-24 Idiopathic pulmonary fibrosis
• VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting
  2022-503055-26-00 9 2023-10-30 Unresectable recurrent or metastatic HPV16 (Human Papilloma Virus) pos
• A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c … Recruiting
  2023-504265-23-00 4 2023-10-23 Crohn's disease
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca … Recruiting
  2022-501703-27-00 5 2023-07-05 Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting
  2024-513185-19-00 9 2022-07-13 Extensive stage small cell lung cancer (ES-SCLC)
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting
  2024-516993-31-00 5 2026-05-11 Renal Cell Carcinoma
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30 Obesity
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases

Showing 49–72 of 336 trials